BIO CONVENTION 2016 | BRAZILIAN PAVILION
1
Promoted by
2
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Brazilian Pharma Solutions ......................................................................................................................................04 Abiquifi ..............................................................................................................................................................................05 Apex-Brasil ......................................................................................................................................................................06 Partners............................................................................................................................................................................. 07 Janssen............................................................................................................................................................................ 09 Lilly........................................................................................................................................................................................10 Gusmão & Labrunie Intellectual Property.......................................................................................................... 11 Thermo Fisher Scientific ............................................................................................................................................12 Kasznar Leonardos Intellectual Property Brazil ...............................................................................................13 Libbs Pharmaceutical Industry................................................................................................................................14 Thomson Reuters .........................................................................................................................................................15 Cristália .............................................................................................................................................................................. 17 Techtrials ..........................................................................................................................................................................18 Biolab Pharmaceutical................................................................................................................................................19 Supera Technology Park...........................................................................................................................................20 Anbiotec - Biotechnology and Life Sciences Companies Association.................................................21 Bio-Manguinhos / Fiocruz........................................................................................................................................ 22 Aché .................................................................................................................................................................................. 23 Braga, Carvalho & Octaviani Law Firm - BCO Law....................................................................................... 24 Bioclin ............................................................................................................................................................................... 24 Biolotus Biotech............................................................................................................................................................ 25 Biomm Technology.................................................................................................................................................... 25 Blau Biotech.................................................................................................................................................................... 26 Bionovis ........................................................................................................................................................................... 26 Biopolix Biotechnology..............................................................................................................................................27 Biozeus...............................................................................................................................................................................27 Blanver .............................................................................................................................................................................. 28 Codon Biotechnology............................................................................................................................................... 28 DGlab ................................................................................................................................................................................ 29 Ecovec .............................................................................................................................................................................. 29 Eurofarma .......................................................................................................................................................................30 Farmacore Biotech.......................................................................................................................................................30 FK Biotech ........................................................................................................................................................................31 Geloab ...............................................................................................................................................................................31 Hypermarcas.................................................................................................................................................................. 32 ICF - Institute of Pharmaceutical Sciences....................................................................................................... 32 JHS Biomaterials........................................................................................................................................................... 33 Linhagen........................................................................................................................................................................... 33 Liobras .............................................................................................................................................................................. 34 Orygen Biotechnology.............................................................................................................................................. 34 Pluricell Biotech............................................................................................................................................................. 35 Visiongen.......................................................................................................................................................................... 35 Government Institutions............................................................................................................................................ 36 BIO CONVENTION 2016 | BRAZILIAN PAVILION
3
The Brazilian Pharmachemical Industry Association (Abiquifi) and the Brazilian Trade and Investment Promotion Agency (Apex-Brasil) develop, in partnership, the project of the internationalization of pharmachemical and pharmaceutical brazilian sectors. They also have the support of other industry organizations as Sindusfarma, Alanac, Interfarma, Prรณ-Genericos and Abifina. The initiative aims to expand the participation of companies from Brazilian pharmaceutical and pharmachemical productive chain into the international scenario, seeking to increase exports, exchange of technology, attraction of investments and internationalization of the sector. It promotes actions in business intelligence, international marketing, prospective missions, building export capacity, international fairs, business rounds and trade missions directed to different target markets, including countries from all five continents.
brazilianpharmasolutions@abiquifi.org.br + 55 (11) 2638-4487 / 4519 www.brazilianpharmasolutions.com.br
4
BIO CONVENTION 2016 | BRAZILIAN PAVILION
The Brazilian Association of Pharmaceutical Ingredients Producers (Abiquifi) is a nonprofit company founded in 1983 and brings together companies from the pharmachemical and pharmaceutical inputs’ sector. Its main goal is stimulate the development of their production in Brazil. Abiquifi has its own website on the internet (www.abiquifi.org.br) with various market information, statistics, relevant laws and many other important data; it publishes an annual index which records all pharmachemicals and pharmaceutical inputs produced in Mercosur, besides coordinating the project of internationalization of the sector.
abiquifi@abiquifi.org.br +55 21 2220-3005 www.abiquifi.org.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
5
ABOUT APEX-BRASIL
The Brazilian Trade and Investment Promotion Agency (Apex-Brasil) works to promote Brazilian products and services abroad, and to attract foreign investment to strategic sectors of the Brazilian economy. The Agency carries out several commercial promotion initiatives, such as commercial and prospective missions, business rounds, support to the participation of Brazilian companies in major business fairs, and visits of foreign buyers and opinion formers to assess the Brazilian productive structure, among other business platforms aimed to strengthen the Brazil brand. In addition to the headquarters in Brasilia, Apex-Brasil has nine business offices in important global markets, to assist in the process of internationalization of Brazilian companies, prospect business opportunities and enhance national participation in major global markets, also serving as a reference for the attraction of foreign investment. The business offices are located in Asia (Beijing, China), the Middle East (Dubai, United Arab Emirates), North America (Miami and San Francisco, USA), South America (Bogotรก, Colombia), Central America and the Caribbean (Havana, Cuba), Europe (Brussels, Belgium), Eurasia (Moscow, Russia) and Africa (Luanda, Angola).
apexbrasil@apexbrasil.com.br +55 (61) 3426-0202 www.apexbrasil.org.br
6
BIO CONVENTION 2016 | BRAZILIAN PAVILION
ais logo Sindusfarma
Partners
Abifina - Brazilian Fine chemicals industries, biotechnology and Specialties Association www.abifina.org.br
Alanac - National Pharmaceutical Laboratories Association www.alanac.org.br
Interfarma - National Pharmaceutical Laboratories Association www.interfarma.org.br
Pro Genéricos - Brazilian Generic Medicines Industry Association www.progenericos.org.br
Sindusfarma - São Paulo State’s Pharmaceutical Industry Business Association www.sindusfarma.org.br
ersões Oficiais om degradê antone
Grupo Farma Brasil - Pharma Brazil Group www.grupofarmabrasil.com.br
ersões Oficiais om degradê MYK
rsão Secundária m degradê - Positiva BIO CONVENTION 2016 | BRAZILIAN PAVILION ntone
Alfob - Association of Brazilian Official Pharmaceutical Laboratories www.alfob.org
7
SPONSORS
8
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Janssen is the pharmaceutical company of the Johnson & Johnson family of companies, which also includes the Consumer and Medical Devices businesses – that together touch more than one billion lives worldwide every day. Janssen’s focus is to offer solutions for unmet medical needs in five therapeutic areas: Oncology & Hematology, Neuroscience, Infectious Diseases & Vaccines, Immunology and Cardiovascular & Metabolism. These needs are more complex than ever. Therefore, the company creates value through innovation and seeks solutions wherever they are, collaborating with the very best in science to generate healthcare solutions that transform lives around the world. Overall, Janssen has more than 10 new products in late development and 70 molecules in early stages of research, as well as approximately 150 ongoing projects. In Brazil, Janssen is ranked as the third pharmaceutical company in number of clinical trials (2015), with 48 projects involving 723 institutions and more than 1,500 health professionals.
Camila Higuchi chiguchi@its.jnj.com +55 (11) 3030-4708 www.janssen.com
BIO CONVENTION 2016 | BRAZILIAN PAVILION
9
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.
Fรกbio Oliveira +55 (11) 2144-5029 f_oliveira@lilly.com www.lilly.com
10
BIO CONVENTION 2016 | BRAZILIAN PAVILION
What is the value of innovation? Gusmão & Labrunie is one of Brazil’s leading Law Firms committed to protect your passion, talent, dedication, vision, projects and creations. Exclusively focused on Intellectual Property, we provide a broad range of legal and technical services of the highest caliber, being proud of having a competent and creative multidisciplinary team of lawyers and patent specialists to assist Brazilian and international clients of the most varied sizes and sectors. We offer superior level of personalized service and hold in-depth knowledge of our clients’ field of expertise, presenting the most effective and tailor-made strategic IP solutions in technologies as diverse as life sciences, pharmaceuticals, engineering and entertainment, assisting from simpler technical patent or trademark prosecution and counseling to challenging litigation matters. Our team is known for handling the most complex issues and upholds excellence standard in protection, guidance and management of intellectual property.
Ana Paula Celidonio acelidonio@glpi.com.br +55 (11) 2149-4500 www.glpi.com.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
11
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.
Daniela Queiroz daniela.queiroz@thermofisher.com +55 (11) 2367-2192 / 93 / 94 www.thermofisher.com
12
BIO CONVENTION 2016 | BRAZILIAN PAVILION
EXCELLENCE IN THE MANAGEMENT OF INTELLECTUAL PROPERTY. THIS IS OUR BRAND. With the experience of a highly qualified, multifunctional team and with almost a century of experience, we operate in the registration and protection of trademarks, patents and any intellectual assets of several segments. The deep understanding of each market combined with technical and legal analysis, makes Kasznar Leonardos a firm with full ability in solving the most complex Intellectual Property issues. Our Pharma&Biotech team is formed by specialized professionals and led by João Luis Vianna, a partner with double degree – graduated in law and medicine – characteristic that makes us reference in this field. In regards to our strengths, we can say that is what our firm stands out for: • COMMITMENT TO ETHICAL VALUES • FOCUS ON QUALITY • PERSONALIZED TREATMENT AND PARTNER AVAILABILITY • QUICK AND CLEAR • COMMUNICATION • THE WORK IS ALWAYS SUPERVISED BY A PARTNER • IP EDUCATIONAL PROGRAMS FOR OUR CLIENTS
Priscila Kashiwabara priscila.kashiwabara@kasznarleonardos.com +55 (11) 2122-6600 www.kasznarleonardos.com.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
13
We are building the future Helping people achieve plenitude in life. With this purpose we´re building the first Brazilian biological facility, where we will produce our biosimilar and innovative biological active substances for the treatment of cancer, autoimmune and other diseases. It will be the largest single-use plant in Latin America, with a full operation capacity for the production of more than 400 kg of biological therapeutic molecules. We will act in the whole process – from the live cell culture, production and purification of biological drugs to the fill and finish processes.
Márcia Martini Bueno marcia.martini@libbs.com.br +55 (11) 3879-2500 www.libbs.com.br
14
BIO CONVENTION 2016 | BRAZILIAN PAVILION
From scientific discovery to intellectual assets’ protection, the Thomson Reuters Intellectual Property & Science business assists academic institutions, governments, corporations and law firms throughout the life cycle of innovation. The aim of our solutions is to maximize our customers return on investment in R&D and support well informed, faster and better decision making. Thomson Reuters accelerates the pace of innovation by enabling today’s innovators to discover, protect and commercialize their inventions across the Lifecycle of Innovation.
Discover Thomson Reuters enables you to find the signal in the noise of today’s massive volume of data with the world’s most trusted information
Protect Thomson Reuters empowers you with intuitive technology and innovation management solutions to protect your inventions
Commercialize Thomson Reuters connects you to communities of insightful experts and networks to maximize the returns on your innovation investments
Cristian Madoery cristian.madoery@thomsonreuters.com +55 (11) 3613-8400 www.thomsonreuters.com.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
15
EXHIBITORS
16
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Cristália ranks a leading position in anesthetic products in LatAm: its 6 plants in Brazil and Argentina manufacture drug products (DP) and drug substances (DS) used in anti-HIV therapies, psychiatry, pain management, oncology, and biotechnology, also exporting to more than 30 countries.
BIOTECHNOLOGY In 2013 Cristália started up a cGMP Biotechnology facility to produce the DS Somatropin, Trastuzumab, and Etanercept, based on prokaryotic and mammalian cells expression systems in two distinct and segregated production lines. The second cGMP facility was opened in 2014 for manufacturing animal-free Collagenase DS.
KOLLAGENASE Since 1979 Cristália manufactures and markets the ointment KOLLAGENASE for wound treatment using a DS from an international supplier, detaining over 60% of Collagenase Brazilian market. Strategically, Cristália developed a new Collagenase, obtained from a bacterial strain from Brazilian Biodiversity, using an animal-free manufacturing process. On April 2016 ANVISA approved this new Collagenase as the DS for KOLLAGENASE ointment.
Vinícius Gil vinicius.gil@cristalia.com.br +55 (11) 3723-6529 www.cristalia.com.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
17
Techtrials was founded 8 years ago aiming to be the Leading Brazilian CRO and offering the best service solutions for Multinational and Local Pharma Companies. Today, Techtrials reached it’s objective and is the Leading Brazilian CRO which has been growing exponentially in the past 5 years (CAGR +59%) through high quality clinical research and outsourcing services coupled with distinctive responsiveness and expertise of our team. Our core services comprise: Outsourcing (Services & Contractors), Full Service Project Management, Monitoring, Regulatory Affairs, Bioequivalence Management & Monitoring (Analytical & Clinical), Medical Services Management (Protocol Writing, Epidemiology, HEOR, Market Access, Biostatistics) and Drug Development Strategy. We have fully managed projects in most therapeutic areas and all phases of clinical research. Additionally, Techtrials is now preferred vendor for several Top Pharma companies and was successfully audited and rated by multiple Pharmas and also Dun & Bradstreet.
Douglas Valverde doug.valverde@ttrials.com +55 (11) 3033-9740 / USA +1 908.547.7447 www.ttrials.com
18
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Privately owned, Biolab is a brazilian pharmaceutical company founded in 1997, today among the Top 15 on the ethical Market in Brazil. Absolut leader on Cardiovascular drugs market in Brazil, is also focused on gynecology, dermatology, rheumatology, orthopedics, pediatrics, endocrinology, geriatrics and GP. Biolab reached USD 420 MM on sales in 2015. Its sales force has more than 1200 collaborators fully dedicated to promoting company’s portfolio. Besides national and international Universities and Research Centers, Biolab has partnerships with some of the most important pharmaceutical companies of the world. Biolab has kick-started its internationalization strategy, announcing investments of USD 40 million will be made over the next two years to set up the firm’s first research and development (R&D) center outside of Brazil in the province of Ontario, Canada. Further, Biolab has installed a business unit in Miami, EUA – with a focus on the partnerships expansion with multinational.
Ana Paula Branco abranco@biolabfarma.com.br +55 (11) 3573-6165 www.biolabfarma.com.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
19
SUPERA, managed by FIPASE (legal entity), develops and strengthens the local industry to expand national and internationally, attracts technology based companies and stimulates the creation of new ones. Has actually 50 companies and is preparing 126 plots (totalizing 150.000 sq meters) for companies installation. Also participates in the governance of the two clusters: the cluster of Health and Software, which together sum 300 companies. SUPERA is the most significant entrepreneur institution of the region and was elected as the best business incubator of Brazil and in LatAm’s top 10.
Saulo Rodrigues saulo@fipase.org.br +11 (16) 3315-0735 www.superaparque.com.br
20
BIO CONVENTION 2016 | BRAZILIAN PAVILION
ANBIOTEC - Biotechnology and Life Sciences Companies Association - is a private, non-profit organization that officially represents companies in the biotechnology and health sector in Brazil. ANBIOTEC contributes to the strengthening innovation and business competitiveness, providing services and performing actions such as: support for trade promotion through events and business meetings, support for participation in national and international fairs and events, management training programs business, quality management and support for certification of products and processes, trade missions, international support and partnerships stimulating the international market and foreign trade.
Vanessa Silva vanessasilva@ambiotec.org.br +55 (31) 3401-1124 www.ambiotec.org.br
BIO CONVENTION 2016 | BRAZILIAN PAVILION
21
The Institute of Technology in Immunobiologicalsy (Bio-Manguinhos) is an unit of Fiocruz that has been producing vaccines, reagents for diagnosis and biopharmaceuticals since 1976, year of its creation. For 40 years, the Institute has been expanding the population´s access to health care by offering new products to prevent, diagnose and treat diseases. This action goes beyond the borders of the country, benefiting developing countries, especially in Africa and Latin America. In order to establish itself as the largest public laboratory of the country, Bio-Manguinhos wrote parts of the history of public health in Brazil. Partnerships with institutions - public and private - ensure technology transfer agreements and technological development, contributing to the development of their its projects and a faster incorporation of production know how ledge. The portfolio of the Institute grows annually. It consists of 28 products: 10 vaccines, 13 reagents for diagnosis and 5 biopharmaceuticals. Every year, millions of units are provided to the programs of the Ministry of Health.
Renata Ribeiro GĂłmez de Sousa Renata.ribeiro@bio.fiocruz.br +55 (21) 3882-9583 www.bio.fiocruz.br
22
BIO CONVENTION 2016 | BRAZILIAN PAVILION
companies
Aché is a leading Brazilian pharmaceutical group, ranked #1 in the Rx market. ACH24 (vitiligo) and ACH36 (anxiety) are the company’s most promising NCE’s in clinical development. Aché also offers a variety of “me better” products, based on differentiated technology platforms (Smart Modulated Technologies).
Joao Paulo Vissoci joao.vissoci@ache.com.br +55 (11) 2608-6516 www.ache.com.br BIO CONVENTION 2016 | BRAZILIAN PAVILION
23
Braga, Carvalho & Octaviani Law Firm – BCO Law, is specialized in Economic Law, providing legal advisory in areas such as environmental law, regulatory affairs regarding the biotech industry and Intellectual Property. Formed by lawyers with dynamic and distinguished careers, BCO Law prioritizes constant attention and dedication to its clients. Our lawyers are committed to ally proximity and technical quality in order to provide precise answers and excellent results to their clients.
Marco AurĂŠlio Cezarino Braga braga@bcoa.com.br +55 (11) 3113-1700 www.bcoa.com.br
Quibasa/Bioclin, one of the greatest Brazilian companies in the in vitro diagnostics segment, had been investing for more than 39 years in quality, research and development. In the past years we had consolidated our presence in the international IVD market exhibiting in the biggest shows around the globe, such as: HOSPITALAR, MEDICA, ARAB HEALTH / MEDLAB, BIO and AACC. Taking part in those shows, besides bringing notoriety to the Bioclin trademark, it strengths the continuous work for a better product and service, starting with professionals committed with quality. Silvio Arndt silvioarndt@bioclin.com.br +55 (31) 3439-5454 www.bioclin.com.br 24
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Biolotus Biotech is a pharmaceutical company specializing in R&D, registration, manufacture, promotion and worldwide distribution of pharmaceutical and biopharmaceutical products. Biolotus has a close cooperation with its partners, and our well-established worldwide network provides a competitive advantage, placing us as strategic partners. We provide a long-lasting service through our expertise in pharmaceutical development, registration and market penetration. Our mission is To Serve! JoĂŁo Transmontano jtransmontano@biolotus.com +55 (21) 2480-2405 www.biolotus.com
Biomm is a company resulting from the spin-off of BiobrĂĄs, a pioneering player in pharmaceutical biotechnology in Brazil. It is a publicly held corporation with stocks traded at BOVESPA+ Stock Exchange (BIOM3). The company is building a state-of-theart biopharmaceutical plant in Minas Gerais to manufacture insulin products and other biosimilars using a technological platform developed in Brazil and patented in the USA, Europe and Asian countries.
Lucas Ciuffardi lucas.ciuffardi@biomm.com +55 (31) 3299-1000 www.biomm.com BIO CONVENTION 2016 | BRAZILIAN PAVILION
25
Blau Farmacêutica is a Brazilian pharmaceutical, private limited company. The business, which was founded in 1988 by a very young yet visionary Marcelo Hahn, has over 25 years of history acting on important markets, spread over various continents. The company was pioneer in the development of a number of different recombinant proteins, such as Alfaepoetin, Somatropin, Filgrastim, Betainterferon, Alfainterferon and others biosimilars, selling specially in Latam and Asian countries.
Mariana Andrade Lourenson mlourenson@blau.com.br +55 (11) 4615-9400 www.blau.com.br
Bionovis is a pharmaceutical biotechnology JV composed of four of the largest Brazilian pharmaceutical companies (Aché, EMS, Hypermarcas and União Química) which, together, hold 34% of the Brazilian market with a total of US$ 6.5 bi sales. Bionovis is engaged in R&D, manufacture and marketing of novel and biosimilar biopharmaceuticals. We are open to discuss in-licensing, technology transfer, partnering and/or co-development opportunities in the biopharmaceutical arena.
Thiago Mares Guia thiago.guia@bionovis.com.br +55 (19) 3881-5000 www.bionovis.com.br 26
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Biopolix is a Brazilian startup focused on the development and production of an innovative biodegradable bioplastic. The novelty is to produce biopellets from renewable sources through a clean process without chemical pollutants. Our products already have patent application. We aim to change the obtaining process of biopellets to achieve the existent plastic production chain and apply for another patent. Biopolix is at Supera Incubator in RibeirĂŁo Preto-SP.
Luisa Vendruscolo luvendrus@gmail.com +55 (16) 99784-7719 / +55 (51) 9105-9561 www.biopolix.com.br
Biozeus is a Brazilian biopharmaceutical company totally focused on identifying innovations from Brazilian universities and research institutes and to advance and derisk these compounds until proof of clinical concept. With a decentralized company model and an experienced team of national and international experts, Biozeus is able to advance projects with more speed, reduced risk in a more cost effective manner than traditional start-ups.
Luis Eduardo Caroli caroli@biozeus.com.br +55 (21) 2523-9089 www.biozeus.com.br BIO CONVENTION 2016 | BRAZILIAN PAVILION
27
BLANVER is a Brazilian company with more than 30 years of experience. We develop, manufacture and sell Excipients, APIs and Finished Dosage Formulations with quality and competitiveness within HIV, Hepatitis and Osteoporosis therapeutic classes, for the health and well-being of people. Our growth strategy is to expand our business internationally through alliances and partnerships. Currently, we are looking for expanding our business into the Oncology area through partnerships (in-licensing).
Érica Silveira erica.silveira@blanver.com.br +55 (11) 4138-8211 www.blanver.com.br
The Codon Biotechnology is a company that operates and is a reference in the field of genetics and molecular biology. Offers tests in cytogenetics, molecular biology and paternity tests following the strict international quality standards. The company operates throughout the Brazilian territory and has experienced professionals , masters and doctors.
Helena Beatriz Martins Da Costa helenacosta@codon.com.br + 55 (31) 3324-1211 / + 55 (31) 3245-1211 www.codon.com.br 28
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Dglab is a Synthetic Biology Translational Center focused on the development of diagnosis and rapid molecular tests. We are located at Supera, the best Braz ilian Technology-Based Business Incubator, and our aim is to deliver innovative, portable, low cost and easy-to-use molecular tools.
Rodrigo Caldeira Ramos caldeira2@gmail.com +55 (16) 99750-5161
Ecovec is a biotechnology and bioinformatics company created to help health managers make the best decisions for the prevention of Aedes transmitted diseases. Our platforms integrate information about vector, virus and human disease in a spatial and timely scale surveillance to optimize prevention and vector control measures. Disease prevention can be obtained with more effective management based on real time information of disease occurrence, risk and efficiency of control measures.
CecĂlia De Almeida Marques Toledo cecilia@ecovec.com + 55 (31) 3284-1007 / +55 (31) 3401-1038 www.ecovec.com BIO CONVENTION 2016 | BRAZILIAN PAVILION
29
With 44 years of existence, Eurofarma is the first Brazilian multinational pharmaceutical company, recognized by promoting access to health and quality of life with reliable treatments at a fair price. With solid presence in 20 countries in Latin America besides from offices in Africa, became the first company to launch a biosimilar medicine in Latin America, Fiprima. In 2015, invested 5.3% of its net sales on research and development and reached revenues of R$ 2.9 billion, 11% higher than the previous year.
Emilio Maganha Neto emilio.neto@eurofarma.com.br +55 (11) 5090-8493 www.eurofarma.com.br
Farmacore is a biotech company that develops and improves value in innovative biotech products for human and veterinary sector (immunobiologicals and immunomodulators for infectious diseases, allergy, autoimmune diseases and cancer). Farmacore owns GMP Bioprocess Facilities for DNA vaccines and recombinant proteins. We also offer analytical assays in GLP for immunogenicity and bio analytical determinations; microbiological monitoring assays; cloning, expression and purification.
Helena Faccioli Lopes helena@farmacore.com.br +55 (16) 3629-3782 www.farmacore.lwsite.com.br 30
BIO CONVENTION 2016 | BRAZILIAN PAVILION
Late stage clinical immuno-oncology company. Autologous tumor cell-based discovery platform, with a potent multi-antigenic immune response. Its main product ProstateTheraCell© is based on its proprietary novel technology that using the patient’s own cancer cells to elicit a broad, multi-antigen immune response in cancer patients.
Fernando Kreutz fkreutz@fkbiotec.com.br +55 (51) 3352-6863 www.fkbiotec.com.br
Geolab has conquered the position of fastest growing farmaceutical industry in the Brazilian market, with which has established itself among the TOP 10 Corporations with 100% national capital. It is with pride that we carry our special acknowledgements to our partners and clients for believing that it’s possible to bring quality health with accessible prices to all of Brazil.
Georges Hajjar Jr. geo@geolab.com.br +55 (62) 4015-4816 www.geolab.com.br BIO CONVENTION 2016 | BRAZILIAN PAVILION
31
Founded in 2001, Hypermarcas is Brazil’s national champion in pharmaceutical products. With about 14% market share in units, it ranks #1 in the Brazilian market, competing in all relevant segments of the sector. With leadership positioning in several categories, Hypermarcas ranks #1 in OTC drugs, #2 in branded & unbranded generics, #2 in dermocosmetics and #5 in prescription products. Its strength is based upon lowcost operations, strong brands and agile organization.
Fernando Kalil fernando.kalil@hypermarcas.com.br +55 (11) 3627 5520 www.hypermarcas.com.br
The Institute of Pharmaceutical Sciences (ICF) has been founded in 2002 and it has been the first Brazilian bioequivalence and bioavailability laboratory to get certified by ANVISA and the Instituto de Salud Publica del Chile (ISP). It is one of the largest pharmaceutical research centers in Brazil and in Latin America. ICF offers high technology, innovation and expertise that assure the credibility and quality of our services.
Laura Moreira Rezeck laura.rezeck@icf.com.br +55 (62) 3240-8700 www.icf.com.br 32
BIO CONVENTION 2016 | BRAZILIAN PAVILION
JHS Biomateriais is a materials technology company specializing in human bone grafting. The basis of our materials are a hydroxyapatite of high purity and purified collagen. Given the Brazilian market for over 17 years, and certified by ISO 9001 and ISO 13485, we are currently working to achieve CE marking and registered with the FDA in order to conquer the global market.
Sheyla Maria De Castro Mรกximo Bicalho diretoria@jhs.med.br +55 (31) 3484-9355 www.jhs.med.br
LINHAGEN is a private held Brazilian company specialized in the development of molecular tools for horses, cattle and ovines. The company provides services on genetic identification, molecular diagnostics and meat traceability. We seek companies interested in technological and financial partnerships.
Kรกtia Torres De Souza katia@linhagen.com.br +55 (31) 3295-1420 www.linhagen.com.br BIO CONVENTION 2016 | BRAZILIAN PAVILION
33
We design, develop, produce and commercializing freeze-dryers. Freeze-drying is also known as lyophilisation or cryodesiccation. LIOTOP was established as an initiative among researchers & entrepreneurs to provide technological solutions for freezedryers. We are the main South America Company exclusively dedicated to freezedryer manufacturing and our equipment and process are located in pharmaceutical industries, R&D centers, universities, some industrial food plants and small productions.
Julien Fauvel julien@liobras.com.br +55 (16) 3372-4000 www.liobras.com.br
Orygen, a joint venture of the Brazilian pharmaceutical companies Biolab and Eurofarma, is focused on the development, manufacture and marketing of monoclonal antibodies and vaccines for disorders that affect Brazil and other emerging economies. Orygen´s initial products will be biosimilar antibodies manufactured using technology transferred from Pfizer Inc. to supply the Brazilian Public Health System. Orygen is also committed to develop innovative medicines that will have impact on the treatment of patients with severe diseases to broaden the range of highest quality therapeutic options. Otåvia Caballero ocaballero@orygen.com.br +55 (11) 3044-3995 www.orygen.com.br 34
BIO CONVENTION 2016 | BRAZILIAN PAVILION
PluriCell Biotech is the first stem cell company in the South hemisphere to use the potential of iPS cells to produce human adult tissue specific cells with high quality and purity. Currently we already have human cardiac cells in stock that express all necessary markers, contract spontaneously and respond to chemical stimuli. We are developing skin and liver cells. We believe these cells are the future of drug development as they are the most assertive in vitro technology available.
Marcos Valadares marcos.valadares@pluricellbiotech.com +55 (11) 3039-8359 www.pluricellbiotech.com.br
The company is also a Lab Service Provider for International Genomic Companies. We have technology license agreement with National and International Companies. Through these agreements International Companies can offer their services and products in the country without facing Brazilian and international legislation regarding shipment of biological samples.
Kรกtia Torres katia@visiongen.com.br +55 (31) 2516-0009 www.visiongen.com.br BIO CONVENTION 2016 | BRAZILIAN PAVILION
35
Government Institutions
36
BIO CONVENTION 2016 | BRAZILIAN PAVILION
The Brazilian Agency for Industrial Development (ABDI) was created by the federal government in order to perform the industrial policy in line with the policies of science, technology, innovation and foreign commerce. ABDI acts building an agenda of actions to improve the business environment, investments, technology and innovation. The Agency works towards creating the favorable institutional environment for the development of biotechnology in Brazil, among other industrial sectors. Its main goal is to establish a collaborative agenda for the implementation of the Biotechnology Development Policy on strategic sectors like health and industrial biotechnology. Its efforts aim to increase the number of cooperative projects between the Academic Community, companies, and Government under the national agenda. Other initiative is the Brazil Diaspora Network, a network of Brazilian professionals to generate business and projects in areas of intensive knowledge. It supports partnerships between international technological and innovative organizations with their counterparts in Brazil.
The Brazilian Development Bank (BNDES) is the main financing agent for development in Brazil. The Bank offers several financial support mechanisms to Brazilian companies of all sizes as well as public administration entities, enabling investments in all economic sectors.
The Butantan Institute has the mission of developing biological products for public health, undertaking basic and applied research, and promoting scientific knowledge. The Institute, linked to the SĂŁo Paulo State Secretary for Health, is currently responsible for providing an expressive amount of all of the nationally produced serums and vaccines distributed without cost to the entire population of the country by the Brazilian Health Ministry through the Unified Health System (SUS).
CAPES is a Foundation within the Ministry of Education in Brazil whose central purpose is the support and evaluation of graduate education. CAPES is a government agency awarding scholarship grants to graduate students at universities and research centers in Brazil and abroad.
BIO CONVENTION 2016 | BRAZILIAN PAVILION
37
Government Institutions Finep is a Brazilian government agency specialized in promoting innovation through financing Brazilian innovative projects. This means that companies, universities, technological institutes and public or private institutions can be financed through grants, loans with low rates and equity, as well as receive guidance and counseling for projects. What differentiates Finep is its ability to integrate teams and combine human, technological and financial resources to promote Brazilian innovation, from R&D to market-driven projects.
INDI, the investment promotion agency of Minas Gerais, works to facilitate new investments and to support the companies established in the state. Minas Gerais is located in the Southeast Brazil and has a diverse economy. In the Life Sciences sector, the state excels in Biotechnology, Animal Genetics and Medical Devices. A lot of important companies are already here, such as GE Healthcare, Philips, Novo Nordisk and Alta Genetics. Get to know you too the business opportunities in Minas Gerais!
The Ministry of Development, Industry and Foreign Trade (MDIC) is responsible for policy development for the industry, trade and service sectors and coordinates a number of programs and initiatives aimed at supporting competitiveness, investment and innovation in Brazil.
The Ministry of Health (MS) is responsible for the development and execution of programs and policies aimed at health promotion, prevention and health care. It also leads, together with states and municipalities, the Brazilian Unified Health System.
Minas Gerais, in addition to the privileged location, has the third largest economy of the country. We are an outstanding reference in coffee production and we have the title of being the largest center of biotechnology companies in Brazil. This is how our more than 850 municipalities keep their development on. The State Secretariat of Science, Technology and Higher Education (SECTES) invests in the development of Minas Gerais by promoting researches, the generation and application of scientific and technological knowledge, as well as overseeing the State entities of Higher Education. Minas Gerais: the best place to innovate!
38
BIO CONVENTION 2016 | BRAZILIAN PAVILION
BIO CONVENTION 2016 | BRAZILIAN PAVILION
39
#BLA2016 São paulo | october 26-28 2016 BIO Latin America is the ideal venue to explore the innovation and partnering opportunities in Latin America’s rapidly-growing biotechnology industry. Join high level executives, government leaders, academics and investors from around the globe to discuss trends, navigate industry challenges and policy frameworks, attend company presentations, conduct BIO One-on-One Partnering™ meetings and learn about investment opportunities within this emerging market.
Gain unparalleled access to life science, industrial, biochemical and environmental products and technologies from across Latin America Be at the forefront of the latest industry innovations Arrange unlimited face-to-face meetings with high-value potential partners Learn about the venture capital industry and other funding possibilities in Latin America
10% discount for
2016 BIO Convention antendees
Engage local government bodies, research centers, industry clusters and companies that will help you to succeed in this market
bio.org/latinamerica
WELCOME TO SÃO PAULO
40
CO-HOSTED BY:
40
BIO CONVENTION 2016 | BRAZILIAN PAVILION
strategic partner:
BIO CONVENTION 2016 | BRAZILIAN PAVILION
41